Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Menu
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
ACS
Cancer

New NCDB Annual Report Reveals Cancer Treatment Trends

January 27, 2026

26-ncdblinkedin1.jpg

The ACS recently released its second National Cancer Database (NCDB) annual report in the Journal of the American College of Surgeons (JACS), which includes updated data from the NCDB 2022 adult participant user file. The report provides observations and trends of cancer diagnoses, patient demographics, and treatments, as well as in-depth reports on treatment and outcomes for prostate cancer, esophageal cancer, and melanoma.

One of the key trends noted was the increase in neoadjuvant systemic therapy for several cancers, including a nearly 5-fold rise in gynecologic cancer, a more than 3-fold increase in pancreatic cancer, and a doubling of neoadjuvant therapy in peritoneum, omentum, and mesentery cancer.

The in-depth look at three cancers found noteworthy trends, as well, including the continued increase of nonsurgical treatment for stage 1 prostate cancer, a sharp increase in immunotherapy for esophageal cancer, and that patients with scalp and neck melanomas had the lowest overall survival rates among all invasive melanomas, among others.

“As care at Commission on Cancer-accredited facilities continues to advance, our hope is that this report reflects the vastly changing clinical landscape of cancer treatments using the latest evidence-based treatments,” said Ronald J. Weigel, MD, PhD, MBA, FACS, medical director of ACS Cancer Programs and co-author of the JACS study.